Scientific deep-dive

Which GLP-1 Has the Worst Side Effects?

A network meta-analysis of 33,354 people ranks the drugs symptom by symptom. Orforglipron, the oral pill, tops the nausea ranking, ahead of every injection.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·3 citations

Every GLP-1 causes gastrointestinal side effects, and until recently there was no way to compare them properly. A network meta-analysis of 33,354 adults with overweight or obesity and without diabetes now ranks them. The drug with the highest nausea risk is the one people assume will be gentlest: orforglipron, the oral pill.[1]

The rankings

Gastrointestinal adverse events by drug, in adults with overweight or obesity and without diabetes.
SymptomWhich drugs raised the riskWhich did not
NauseaAll of them. Highest orforglipron, then exenatide, tirzepatide, semaglutide, liraglutide—
VomitingLiraglutide, orforglipron, semaglutide, tirzepatideCagrilintide, exenatide
DiarrheaOthers in the analysisExenatide, cagrilintide, orforglipron
ConstipationSemaglutide, liraglutide, tirzepatide, orforglipron (see correction below)Cagrilintide, exenatide

Nausea, vomiting, diarrhea and constipation were the most common gastrointestinal effects across the board, which will surprise nobody taking one. What is new is being able to say which drug is worse for which symptom.[1]

Correction, September 11, 2026. The constipation row previously named only semaglutide and liraglutide, following the analysis’s abstract. The analysis’s own results also show a raised risk on tirzepatide (risk ratio 3.36, 95% CI 1.70 to 6.63), and the interval it gives for orforglipron, 1.19 to 13.78, does not include 1, although its text calls orforglipron not associated.[1] The labels agree: constipation was reported in 17%, 14% and 11% of people on Zepbound 5, 10 and 15 mg against 5% on placebo, and in 20% to 27% on Foundayo against 9%.[3][2]

The oral pill is not the gentle option

Of every drug ranked, the tablet carried the highest risk of nausea.

Orforglipron came top for nausea and was among the drugs raising vomiting risk. That matters because it is the first approved oral non-peptide in this class and it is being marketed heavily on the convenience of a tablet (see our Foundayo article). Convenience of administration and gentleness on the gut are separate properties, and here they point in opposite directions.

In this analysis orforglipron was not associated with increased diarrhea risk. A drug can rank badly on one symptom and well on another, which is why a single “tolerability” verdict is unhelpful. Orforglipron’s label figures, symptom by symptom and dose by dose, are on Foundayo side effects.

Correction, September 11, 2026. This page previously called diarrhea “the one place orforglipron did well”. The drug’s FDA label, published after the analysis above, does not bear that out: in the two weight-management trials pooled on the Foundayo label, diarrhea was reported by 21%, 23% and 25% of people on the 5.5, 9 and 17.2 mg doses, against 11% on placebo.[2] Read the meta-analysis result as what that analysis found, not as evidence that the tablet spares the bowel. Why diarrhea behaves differently from the other stomach side effects is covered in GLP-1 diarrhea: what has actually been tested.

How to use a ranking like this

  • Match it to your own worst symptom. If constipation is what stopped you before, switching may not solve it: tirzepatide and the oral pill raise it too, and the constipation guide covers what helps. If vomiting is the problem, the picture is different again.
  • Do not read it as a dose-matched comparison. Each drug was tested at its own doses in its own trials. A ranking of drugs is not a ranking of molecules at equivalent exposure.
  • This is a non-diabetic population, deliberately. Rates and rankings differ in diabetes trials, where patients are often on other gastrointestinal-active drugs.
  • Dose and side effects travel together. In this analysis higher doses carried more nausea, vomiting, diarrhea and constipation, with most of the rise at the lower doses,[1] so a ranking that ignored dose and efficacy would mislead.
None of this is a reason to choose or avoid a drug by yourself. It is a reason to tell a prescriber which side effect you are least able to live with, because that is a real input into the choice, and one most consultations never ask about. Our side-effect timeline covers what to expect over the first months, and constipation the one that outlasts the others.

Frequently Asked Questions

It depends on the symptom. For nausea, a network meta-analysis of 33,354 people ranked orforglipron highest, followed by exenatide, tirzepatide, semaglutide and liraglutide. For constipation, semaglutide, liraglutide and tirzepatide all showed increased risk in the analysis's results, and the orforglipron label shows it too.
No. On this evidence it is the opposite. Orforglipron topped the nausea ranking and was among the drugs associated with increased vomiting. Convenience of taking a tablet and gentleness on the gut are separate things.
Exenatide, cagrilintide and orforglipron were not associated with increased diarrhea risk in this analysis. For orforglipron that finding has since been overtaken: its FDA label reports diarrhea in 21% to 25% of people on the drug against 11% on placebo in its weight-management trials.
Not on its own. The rankings are not dose-matched (each drug was tested at its own doses in its own trials), and in this analysis higher doses carried more gastrointestinal side effects. It is information to bring to a prescriber, not a basis for switching yourself.
This analysis was specifically in adults with overweight or obesity and without diabetes. Rates and rankings differ in diabetes populations, where patients are frequently taking other drugs that affect the gut.

References

  1. 1.Ismaiel A, Scarlata GGM, Boitos I, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis International Journal of Obesity. 2025. PMID: 40804463.
  2. 2.Eli Lilly and Company FOUNDAYO (orforglipron) tablets — prescribing information (section 6.1, Table 1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  3. 3.Eli Lilly and Company ZEPBOUND (tirzepatide) injection — prescribing information (section 6.1, Table 1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

GLP-1s and Inflammatory Bowel Disease

The pivotal trials excluded people with IBD, so the evidence is retrospective: 13 of 14 studies. It has not linked GLP-1s to more flares, and that null result deserves careful reading.

6 min read

GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days

Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.

7 min read

What Your Doctor Cannot See

Compounded semaglutide and tirzepatide appear in 8.2% of primary care records. Surveys put real use near 23%, so most of it is invisible to the record and to everything that depends on it.

6 min read

GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.

36% of people with type 1 diabetes and obesity hit a composite of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo. Total daily insulin fell about a third in a second trial.

7 min read

GLP-1 Drugs and Bone: Fracture Risk, Density and What Was Measured

Across 25 studies there was no significant increase in fracture risk and lumbar bone density improved slightly. A 117-trial network analysis of 221,364 people found no GLP-1 signal either.

6 min read

Who Loses More Weight on a GLP-1?

Across 64 randomized trials, the only subgroup difference was sex: women lost 10.9% against 6.8% for men. Age, race, ethnicity, starting BMI and starting HbA1c made no significant difference.

5 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →